Veterinary Medicines Information website

Cefabactin 250 mg tablets for dogs and cats

Authorised
  • Cefalexin monohydrate
Download as PDF

Product identification

Medicine name:
Cefabactin 250 mg tablets for dogs and cats
Active substance:
  • Cefalexin monohydrate
Target species:
  • Cat
  • Dog
Route of administration:
  • Oral use

Product details

Active substance and strength:
  • Cefalexin monohydrate
    262.50
    milligram(s)
    /
    1.00
    Tablet
Pharmaceutical form:
  • Tablet
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QJ01DB01
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Valid
Authorised in:
  • Denmark
Available in:
  • Denmark
Package description:
  • Cardboard box of 9 blisters (Aluminium - PVC/PE/PVDC) of 10 tablets
  • Cardboard box of 6 blisters (Aluminium - PVC/PE/PVDC) of 10 tablets
  • Cardboard box of 4 blisters (Aluminium - PVC/PE/PVDC) of 10 tablets
  • Cardboard box of 3 blisters (Aluminium - PVC/PE/PVDC) of 10 tablets
  • Cardboard box of 25 blisters (Aluminium - PVC/PE/PVDC) of 10 tablets
  • Cardboard box of 2 blisters (Aluminium - PVC/PE/PVDC) of 10 tablets
  • Cardboard box of 8 blisters (Aluminium - PVC/PE/PVDC) of 10 tablets
  • Cardboard box of 7 blisters (Aluminium - PVC/PE/PVDC) of 10 tablets
  • Cardboard box of 5 blisters (Aluminium - PVC/PE/PVDC) of 10 tablets
  • Cardboard box of 10 blisters (Aluminium - PVC/PE/PVDC) of 10 tablets
  • Cardboard box of 1 blister (Aluminium - PVC/PE/PVDC) of 10 tablets
  • Cardboard box containing 10 separate cardboard boxes, each containing 1 blister of 10 tablets

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Generic application (Article 13(1) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Le Vet. Beheer B.V.
Marketing authorisation date:
Manufacturing sites for batch release:
  • Lelypharma B.V.
Responsible authority:
  • Danish Medicines Agency
Authorisation number:
  • 56260
Date of authorisation status change:
Reference member state:
  • Netherlands
Procedure number:
  • NL/V/0201/002
Concerned member states:
  • Austria
  • Belgium
  • Croatia
  • Cyprus
  • Czechia
  • Denmark
  • Estonia
  • Finland
  • France
  • Germany
  • Greece
  • Hungary
  • Iceland
  • Ireland
  • Italy
  • Latvia
  • Lithuania
  • Luxembourg
  • Norway
  • Poland
  • Portugal
  • Romania
  • Slovakia
  • Slovenia
  • Spain
  • Sweden
  • United Kingdom (Northern Ireland)

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
Danish (, TABLETTER 50 MG OG 250 MG)
Published on: 14/03/2026
Download